Downloads: 1
| # | ID | Text | Score | Weight | Similar_ids | Similar_metric |
|---|---|---|---|---|---|---|
| 1 | 10.2 | Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | 0.1 | 5.0 | 10.3,10.4 | 70,15 |
| 2 | 10.3 | HIV positive with antiretroviral therapy excluded | 0.2 | 6.0 | 10.2,10.4 | 70,20 |
| 3 | 10.4 | HIV positive excluded | 0.3 | 7.0 | 10.2,10.3 | 15,20 |
| 4 | 11.1 | Hemoglobin >= 9.0 mg/dl | 0.3 | 7.0 | 11.2 | 90 |
| 5 | 11.2 | Hemoglobin >= 8.0 mg/dl | 0.3 | 7.0 | 11.1 | 90 |
| 6 | 12.1 | Suspected diagnosis of resectable non-small cell lung cancer | 0.2 | 8.0 | 12.2 | 90 |
| 7 | 12.2 | nonsquamous histology | 0.3 | 8.0 | 12.1 | 90 |
| 8 | 12.3 | squamous cell carcinoma are eligible only if the registering site has EA5142 Institutional Review Board (IRB) approved | 0.1 | 3.0 | nan | nan |
| 9 | 13.1 | Suspected clinical stage of IIIA, II (IIA or IIB) or large IB are eligible | 0.2 | 4.0 | 13.2,13.3,13.4,13.5 | 90,90,90,90 |
| 10 | 13.2 | Stage IIIA | 0.3 | 7.0 | 13.1 | 90 |
| 11 | 13.3 | Stage II | 0.3 | 7.0 | 13.1 | 90 |
| 12 | 13.4 | large IB | 0.3 | 7.0 | 13.1 | 90 |
| 13 | 13.5 | size >= 4cm | 0.3 | 7.0 | 13.1 | 90 |
| 14 | 13.6 | IB tumors < 4cm are NOT eligible | 0.3 | 7.0 | 13.7 | 90 |
| 15 | 13.7 | IB tumors < 3cm are NOT eligible | 0.3 | 5.0 | 13.6 | 70 |
| 16 | 14.1 | Completely resected non-small cell lung cancer with negative margins | 0.1 | nan | nan | nan |
| 17 | 15.1 | Eastern Cooperative Oncology Group performance status 0-1 | 0.3 | 8.0 | 15.2 | 90 |
| 18 | 15.2 | ECOG performance status 0-1 | 0.4 | 8.0 | 15.1 | 90 |
| 19 | 16.1 | No patients who have received neoadjuvant therapy | 0.2 | 7.0 | 16.2,16.3 | 90,90 |
| 20 | 16.2 | No Radio Therapy | 0.4 | 7.0 | 16.1 | 90 |
| 21 | 16.3 | No Chemo Therapy | 0.4 | 7.0 | 16.1 | 90 |
| 22 | 17.1 | No locally advanced or metastatic cancer requiring systemic therapy within 5 years | 0.3 | 7.0 | 17.2 | 90 |
| 23 | 17.2 | Metastatic cancer requiring systemic therapy within 5 years excluded | 0.4 | 7.0 | 17.1 | 90 |
| 24 | 18.1 | no secondary primary lung cancer diagnosed concurrently or within 2 year | 0.2 | 7.0 | 18.2,18.3 | 90 |
| 25 | 18.2 | no secondary primary lung cancer diagnosed within 2 year | 0.4 | 7.0 | 18.1 | 90 |
| 26 | 18.2 | no secondary primary lung cancer diagnosed concurrently | 0.4 | 7.0 | 18.1 | 90 |
| 27 | 19.1 | No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4 | 0.2 | 7.0 | 19.2 | 80 |
| 28 | 19.2 | No prior treatment with agents targeting EGFR mutation | 0.4 | 7.0 | 19.1 | 60 |
| 29 | 20.1 | No patients known to be pregnant or lactating | 0.3 | 8.0 | 20.2 | 90 |
| 30 | 20.2 | No patients known to be pregnant | 0.4 | 8.0 | 20.1 | 90 |